Markers of bone resorption in patients treated with pamidronate.

[1]  G. Hortobagyi,et al.  Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. , 1996, The New England journal of medicine.

[2]  M. Kovacs,et al.  Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. , 1996, The New England journal of medicine.

[3]  V. Chinchilli,et al.  Biochemical markers of bone turnover in patients with metastatic bone disease. , 1995, Clinical chemistry.

[4]  A. Lipton,et al.  Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose‐seeking study , 1994, Cancer.

[5]  I. Henderson,et al.  Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. , 1993, The American journal of medicine.

[6]  L. Demers,et al.  Increased urinary excretion of pyridinium cross-links in cancer patients. , 1993, Clinical chemistry.

[7]  D. Eyre,et al.  A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross‐linked N‐telopeptides in urine , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  D. Reid,et al.  Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases , 1991, European journal of clinical investigation.

[9]  P. Woll,et al.  Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). , 1988, British Journal of Cancer.

[10]  R. Cowan,et al.  Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcaemia. , 1988, The Quarterly journal of medicine.

[11]  A. Howell,et al.  Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. , 1988, BMJ.

[12]  D. Thiebaud,et al.  Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Howell,et al.  Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy , 1988, British medical journal.

[14]  S. Robins,et al.  Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. , 1988, Analytical biochemistry.

[15]  J. Hermans,et al.  REDUCED MORBIDITY FROM SKELETAL METASTASES IN BREAST CANCER PATIENTS DURING LONG-TERM BISPHOSPHONATE (APD) TREATMENT , 1987, The Lancet.

[16]  R. Rubens,et al.  3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer. , 1987, British Journal of Cancer.

[17]  S. Robins,et al.  Pyridinium crosslinks of bone collagen and their location in peptides isolated from rat femur. , 1987, Biochimica et biophysica acta.

[18]  J. Body,et al.  Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Adami,et al.  Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. , 1985, The Journal of urology.

[20]  T. Koob,et al.  Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography. , 1984, Analytical biochemistry.

[21]  S. Robins.  Cross-linking of collagen. Isolation, structural characterization and glycosylation of pyridinoline. , 1983, The Biochemical journal.

[22]  Y. Kawanishi,et al.  A novel fluor in insoluble collagen: a crosslinking moiety in collagen molecule. , 1982, Biochemical and biophysical research communications.

[23]  D Fujimoto,et al.  The structure of pyridinoline, a collagen crosslink. , 1978, Biochemical and biophysical research communications.

[24]  C. Galasko.  Mechanisms of bone destruction in the development of skeletal metastases , 1976, Nature.

[25]  R. Theriault,et al.  PP-8-8 Reduction of skeletal related complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy, by monthly pamidronate sodium (AREDIA®) infusion , 1996 .

[26]  Norman Goldstein,et al.  Metastases in carcinoma. Analysis of 1000 autopsied cases , 1950, Cancer.